A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …
[PDF][PDF] Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19
T Feldt, W Guggemos, K Heim, C Lübbert… - Ständiger Arbeitskr der …, 2021 - rki.de
Die SARS-CoV-2-Pandemie stellte unser gesamtes Gesundheitssystem vor große
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …
[PDF][PDF] Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources
Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources
Page 1 1 Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma …
Page 1 1 Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma …
Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and its therapeutic window in a human lung cell model
T Prince, I Donovan-Banfield, H Goldswain… - bioRxiv, 2021 - biorxiv.org
Synopsis Background The UK Medicines and Regulatory Healthcare Agency (MHRA) have
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …
Predictive profiling of SARS-CoV-2 variants by deep mutational learning
The continual evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
2) and the emergence of variants that show resistance to vaccines and neutralizing …
2) and the emergence of variants that show resistance to vaccines and neutralizing …
Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral …
Replicon-based technologies were used to develop reagents and assays for advanced drug
discovery efforts against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
discovery efforts against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Rapid identification of druggable targets and the power of the phenotype simulator for effective drug repurposing in COVID-19
The current, rapidly diversifying pandemic has accelerated the need for efficient and
effective identification of potential drug candidates for COVID-19. Knowledge on host …
effective identification of potential drug candidates for COVID-19. Knowledge on host …
[PDF][PDF] Opciones terapéuticas contra el Covid-19
JE Oliva, S Zelaya, R Dominguez - San Salvador, 2021 - docs.bvsalud.org
Antecedentes La enfermedad Covid-19, causada por el virus SARS-CoV-2, ha generado la
necesidad de desarrollar y reutilizar estrategias terapéuticas que permitan el manejo …
necesidad de desarrollar y reutilizar estrategias terapéuticas que permitan el manejo …
[HTML][HTML] NUDT18 catalyzes the hydrolysis of active metabolites of the antivirals Remdesivir, Ribavirin and Molnupiravir
A Jemth, ER Scaletti, E Homan, P Stenmark… - 2021 - europepmc.org
Remdesivir and Molnupiravir have gained considerable interest due to their activity against
SARS-CoV-2. Cellular hydrolysis of their active triphosphate forms, Remdesivir-TP and …
SARS-CoV-2. Cellular hydrolysis of their active triphosphate forms, Remdesivir-TP and …